Join the club for FREE to access the whole archive and other member benefits.

Louis Hawthorne

Founder and CEO at NaNotics

Lou is an innovator with 25 years of experience in biotech/life science development, artificial intelligence, venture equity, and branding/media design. Lou received a B.A. in English Literature in 1983 from Princeton University, where he was a University Scholar, ran the Film Society and received the Ward Mathis prize.

Lou is a passionate science and technology entrepreneur, with dozens of patents and patents pending. He is the CEO of NaNotics, LLC, which is developing a new nano-medical platform called "NaNots" – which are immune modulating nano-scavengers, which Lou invented and patented. NaNotics has raised a $8.75m to date and is currently building NaNots against cancer, sepsis, autoimmune disease and aging.

Before founding NaNotics, Lou worked for over 10 years with Dr. John Sperling, founder of the University of Phoenix, leading various scientific companies & projects on Sperling’s behalf, including development of commercial cloning capabilities for cat, dog and other species. Lou also served on Sperling's "Greenlight Committee", reviewing $1b in equity investment proposals and approving over $100m, primarily for longevity and oncology research.

Visit website:



See also: Company NaNotics - Company developing a novel nano-medicine platform for treating multiple diseases, including cancer, sepsis, auto-immune disorders and the harmful effects of aging.

Louis Hawthorne is also referenced in the following:

Age-Related Disease Therapeutics Summit

31-May-2023 to 02-Jun-2023

Event about aging and aging related diseases organized by Hanson Wade

Louis Hawthorne News interviews NaNotics' CEO Lou Hawthorne to find out more about Nanots (LEAF) - 04-Nov-2022

Many conditions could be improved by removing signalling that prevents cells operating at their best


Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials


Mayo Clinic is excited to collaborate with NaNotics for cancer treatment

Business Wire - 04-Jan-2022

Ultra-low toxicity NaNots could have a wide variety of applications


Therapeutic plasma exchange can have almost immediate benefit

NEO.LIFE - 24-Jun-2021

Lou Hawthorne, CEO of NaNotics, provides his account of TPE and feeling younger